Alkermes plc (NASDAQ:ALKS) Holdings Decreased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale cut its stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 89.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 5,614 shares of the company's stock after selling 47,903 shares during the period. DekaBank Deutsche Girozentrale's holdings in Alkermes were worth $152,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its stake in shares of Alkermes by 421.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,326,256 shares of the company's stock valued at $225,393,000 after acquiring an additional 6,730,671 shares in the last quarter. Armistice Capital LLC grew its stake in Alkermes by 301.5% during the 2nd quarter. Armistice Capital LLC now owns 2,699,179 shares of the company's stock valued at $65,050,000 after purchasing an additional 2,026,961 shares in the last quarter. Pacer Advisors Inc. increased its holdings in Alkermes by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company's stock worth $135,939,000 after purchasing an additional 1,362,079 shares during the last quarter. American Century Companies Inc. raised its position in shares of Alkermes by 87.1% in the 2nd quarter. American Century Companies Inc. now owns 2,203,456 shares of the company's stock valued at $53,103,000 after purchasing an additional 1,025,905 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Alkermes by 766.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 650,000 shares of the company's stock valued at $15,665,000 after buying an additional 575,000 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Piper Sandler reiterated an "overweight" rating and set a $37.00 price objective (down from $38.00) on shares of Alkermes in a research note on Friday, October 25th. Robert W. Baird boosted their price objective on Alkermes from $37.00 to $38.00 and gave the company an "outperform" rating in a report on Thursday, July 25th. HC Wainwright reaffirmed a "neutral" rating and set a $37.00 target price on shares of Alkermes in a report on Friday, October 25th. StockNews.com upgraded Alkermes from a "hold" rating to a "buy" rating in a report on Sunday, July 28th. Finally, The Goldman Sachs Group decreased their price objective on shares of Alkermes from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.90.

Alkermes Stock Performance

Shares of Alkermes stock traded up $0.12 during trading on Monday, hitting $26.59. 1,094,561 shares of the stock were exchanged, compared to its average volume of 1,832,622. The stock has a market cap of $4.30 billion, a PE ratio of 13.64, a P/E/G ratio of 0.86 and a beta of 0.47. The stock's fifty day moving average is $27.61 and its 200 day moving average is $25.96. Alkermes plc has a 12 month low of $22.06 and a 12 month high of $32.88. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.